Relationship between atomoxetine plasma concentration, treatment response and tolerability in attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder-Reference-Cited by-同舟云学术

Relationship between atomoxetine plasma concentration, treatment response and tolerability in attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder

Published:2009-09-23 Issue:2 Volume:1 Page:201-210
ISSN:1866-6116
Container-title:ADHD Attention Deficit and Hyperactivity Disorders
language:en
Short-container-title:ADHD Atten Def Hyp Disord

Author:

Hazell Philip,Becker Katja,Nikkanen Eija A.,Trzepacz Paula T.,Tanaka Yoko,Tabas Linda,D’Souza Deborah N.,Witcher Jennifer,Long Amanda,Ponsler George,Dittmann Ralf W.

Publisher

Springer Science and Business Media LLC

Subject

Psychiatry and Mental health,Clinical Psychology,General Medicine

Link

http://www.springerlink.com/index/pdf/10.1007/s12402-009-0012-4

Reference20 articles.

1. Bangs ME, Hazell P, Danckaerts M et al (2008) Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder. Pediatrics 121(2):e314–e320

2. Bellgrove MA, Hawi Z, Kirley A et al (2005) Association between dopamine transporter (DAT1) genotype, left-sided inattention, and an enhanced response to methylphenidate in attention-deficit/hyperactivity disorder. Neuropsychopharmacology 30:2290–2297

3. Brown RT, Freeman WS, Perrin JM et al (2001) Prevalence and assessment of attention-deficit/hyperactivity disorder in primary care settings. Pediatrics 107(3):E43

4. Drabick DAG, Gadow KD, Carlson GA et al (2004) ODD and ADHD symptoms in Ukrainian children: external validators and comorbidity. J Am Acad Child Adolesc Psychiatr 43(6):735–743

5. Gadow KD, Nolan EE (2002) Differences between preschool children with ODD, ADHD, and ODD + ADHD symptoms. J Child Psychol Psychiatr 43(2):191–201

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of SLC6A2 and CYP2D6 polymorphisms’ effects on atomoxetine treatment in attention deficit and hyperactivity disorder;European Journal of Clinical Pharmacology;2024-08-19

2. Individualized atomoxetine response and tolerability in children with ADHD receiving different dosage regimens: the need for CYP2D6 genotyping and therapeutic drug monitoring to dance together;Translational Psychiatry;2024-03-19

3. Personalizing atomoxetine dosing in children with ADHD: what can we learn from current supporting evidence;European Journal of Clinical Pharmacology;2023-01-16

4. Therapeutic drug monitoring of atomoxetine in children and adolescents with attention-deficit/ hyperactivity disorder: a naturalistic study;Journal of Neural Transmission;2022-04-07

5. The lowest effective plasma concentration of atomoxetine in pediatric patients with attention deficit/hyperactivity disorder;Medicine;2021-07-09